Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm

Not Applicable

Completed

• Conditions: Ametropia
• Interventions: Procedure: SUPRACOR Regular; Procedure: SUPRACOR Strong

• Registration Number: NCT04617080
• Lead Sponsor: Bausch & Lomb Incorporated

Brief Summary

This is a prospective, comparative, randomized, controlled, open-label, single-surgeon, single-center PMCF clinical study whereby presbyopic patients undergoing refractive surgery will receive a SUPRACOR treatment for the correction in the non-dominant eye and a PROSCAN refractive treatment in the dominant eye to correct for ametropia.

The participants will be randomized to either a SUPRACOR regular (100%) or SUPRACOR strong (130%) treatment with a 1:1 ratio.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-26
• Study First Submitted: 2020-10-30
• Study First Submitted QC: 2020-10-30
• Study First Posted: 2020-11-05
• Status Verified: 2024-02
• Primary Completion: 2024-02-28
• Study Completion: 2024-02-28
• Last Update Submitted: 2024-02-29
• Last Update Posted: 2024-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• presbyopia
• willingness for a refractive presbyopia correction
• signed informed consent form

Read More

Exclusion Criteria

• ocular comorbidity

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SUPRACOR Regular	SUPRACOR Regular	-
SUPRACOR Strong	SUPRACOR Strong	-

Primary Outcome Measures

Name	Time	Method
Binocular Uncorrected Distance Visual Acuity (UDVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 4 m in LogMAR scale under photopic light conditions.

Secondary Outcome Measures

Name	Time	Method
Glare Photic phenomena	3 months follow up	The amount and disturbance of photic glare side effects will be assessed by two methods: 1) Halo and Glare simulator: With this software tool the particant mimics the individual vision perception by adjusting a typical night scene image with the intensity and size of glare and halo; 2) Siepser Glarometer (Gulden Ophthalmics, Elkins Park, PA 19027). This is a target-like device that measures and quantifies post-operative glare. The measurement is of the participants' actual scope and range of monocular glare and halo.
Binocular Corrected Distance Visual Acuity (CDVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 4 m in LogMAR scale under photopic light conditions. Corrected means spectacle corrected.
Binocular Contrast sensitivity	3 months follow up	The contrast sensitivity test consists in assessing the possibility to distinguish the alternation of white and grey fringes of difference contrast with difference frequency. Contrast sensitivity will be assessed under photopic and mesopic light conditions using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) device at 2.5 m.
Binocular Uncorrected Near Visual Acuity (UNVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 40 cm (near distance) in LogMAR scale under photopic light conditions.
Monocular Corrected Distance Visual Acuity (CDVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 4 m in LogMAR scale under photopic light conditions. Corrected means spectacle corrected.
Monocular Uncorrected Intermediate Visual Acuity (UIVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 80 cm (intermediate distance) in LogMAR scale under photopic light conditions.
Binocular Uncorrected Intermediate Visual Acuity (UIVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 80 cm (intermediate distance) in LogMAR scale under photopic light conditions.
Monocular Uncorrected Near Visual Acuity (UNVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 40 cm (near distance) in LogMAR scale under photopic light conditions.
Binocular Defocus Curve	3 months follow up	To assess the visual acuity for different distances, defocus curves under photopic light conditions will be measured using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) device at 4m. This test is performed with best distance corrected refraction and spherical additions ranging from -4.5 D to +1.0 D in 0.5D steps.
Halo Photic phenomena	3 months follow up	The amount and disturbance of photic halo side effects will be assessed by two methods: 1) Halo and Glare simulator: With this software tool the particant mimics the individual vision perception by adjusting a typical night scene image with the intensity and size of glare and halo; 2) Siepser Glarometer (Gulden Ophthalmics, Elkins Park, PA 19027). This is a target-like device that measures and quantifies post-operative glare. The measurement is of the participants' actual scope and range of monocular glare and halo.
Monocular Uncorrected Distance Visual Acuity (UDVA)	3 months follow up	The visual acuity measurements will be assessed using Clinical Trial Suite (M\&S Technologies, Niles, IL, USA) at 4 m in LogMAR scale under photopic light conditions.
Patient-Reported Spectacle Independence Questionnaire (PRSIQ)	3 months follow up	The Patient-Reported Spectacle Independence Questionnaire (PRSIQ) is comprised of 3 questions about the need for glasses or contacts in the past 7 days for distance vision (at least 1.5 meters (m) away), intermediate vision (0.5 m to 1.5 m away), and near vision (\< 0.5 m away). Possible scores range from 1 to 5, with 1 = All of the time and 5 = None of the time for six of the questions; 3 of these questions ask the question in a positive way and 3 of the question ask the question in a negative way, so the higher scores are better for the negative question and are worse for the positive question. There are also 3 questions whether glasses or contacts were needed in the past 7 days with scores of Yes = 1 and No = 2. The results for each question will be summarized separately.
Near Activity Visual Questionnaire (NAVQ)	3 months follow up	The Near Activity Visual Questionnaire (NAVQ) is comprised of 10 questions about performing activities without extra reading spectacles. Each question has responses of 0 to 4, with 0 indicating 'No difficulty' and 4 indicating 'Extreme difficulty'. Any 'Not applicable' responses are scored according to the median overall score for the subject. The scores are summed with total score ranging from 0 to 30. Higher scores indicate more difficulty performing specified activities without spectacles.

Trial Locations

Locations (1)

Asian Eye Institute; 🇵🇭 Makati City, Philippines